738 related articles for article (PubMed ID: 24478400)
1. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Lundberg P; Karow A; Nienhold R; Looser R; Hao-Shen H; Nissen I; Girsberger S; Lehmann T; Passweg J; Stern M; Beisel C; Kralovics R; Skoda RC
Blood; 2014 Apr; 123(14):2220-8. PubMed ID: 24478400
[TBL] [Abstract][Full Text] [Related]
2. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A; Rinke J; Crodel CC; Möbius S; Schäfer V; Heidel FH; Hochhaus A; Ernst T
Br J Haematol; 2023 Jul; 202(2):308-317. PubMed ID: 37139709
[TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
4. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
6. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
7. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
[TBL] [Abstract][Full Text] [Related]
8. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
9. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
11. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
13. Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
[TBL] [Abstract][Full Text] [Related]
14. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
15. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of lymphoproliferative and myeloproliferative neoplasms with simultaneous CALR and JAK2 V617F mutations.
Yang HS
Cancer Biomark; 2016; 17(4):383-389. PubMed ID: 27662324
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.
Chang YC; Lin HC; Chiang YH; Chen CG; Huang L; Wang WT; Cheng CC; Lin J; Chang YF; Chang MC; Hsieh RK; Chen SJ; Lim KH; Kuo YY
Med Oncol; 2017 May; 34(5):83. PubMed ID: 28389907
[TBL] [Abstract][Full Text] [Related]
18. Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation.
Haunstrup LM; Ebbesen LH; Hansen M; Severinsen MT; Aggerholm A
Exp Hematol; 2018 Dec; 68():62-65. PubMed ID: 30292681
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
20. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
Wang J; Hao J; He N; Ji C; Ma D
Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]